World Journal of
Pharmaceutical and Life Sciences

AMBROXOL'S POTENTIAL THERAPEUTIC EFFECTS COMBATING AGAINST NEUROLOGICAL DISORDERS: A REVIEW

*Sudarshan Behere, Rampal Jadhao, Priti Jadhao, Vilas Deshmukh, Pravin Kawtikwar

ABSTRACT

The FDA has approved ambroxol hydrochloride as a medicinal chemical for use as an expectorant. People currently use it as a cough suppressant and a drug to manage asthma. Ambroxol has mucolytic properties and also demonstrates antioxidant, anti-inflammatory, and anaesthetic features. The CNS's consequences are the subject of a continuing investigation. Research has demonstrated that ambroxol can inhibit the growth of microglial cells and decrease the levels of proinflammatory substances in the brain. It has the ability to cross the blood-brain barrier, suggesting potential benefits in protecting the central nervous system (CNS) from various conditions such as spinal cord injury, nervous system inflammation, Parkinson's disease (PD), amyotrophic lateral sclerosis, and Gaucher syndrome. This study aims to assess Ambroxol's impact on the central nervous system (CNS) and its prospective as a therapeutic intervention for neurological disorders. Amyotrophic lateral sclerosis (ALS), It is the most prevalent type of motor neuron disease., primarily impacts found on adults. This condition is characterized by a significant metabolic aspect that influences its progression and leads to the deterioration of the neurons containing of both upper and lower motor neurons. In about two-thirds of ALS patients, metabolic issues play a role in worsening their symptoms. Additionally, ALS disrupts the function of complex lipids called glycosphingolipids, a phenomenon observed in other brain-wasting diseases. This interruption might enable successful therapy. In mice with the SOD1G86R ALS model, the enzyme glucocerebrosidase (GBA 2), which breaks down glucosylceramide, is active more than usual in their central nervous systems. Researchers have shown that ambroxol, a molecule acting as a chaperone to block GBA2, slows down the disease's progression in these mice. Clinical trials are currently testing Ambroxol for Parkinson's disease and Gaucher disease, and exploring it as a potential treatment for ALS.

[Full Text Article]   [Download Certificate]